Hunan Hansen Pharmaceutical Management

Management criteria checks 3/4

Hunan Hansen Pharmaceutical's CEO is Zhengqing Liu, appointed in Jan 2008, has a tenure of 16.83 years. directly owns 1.42% of the company’s shares, worth CN¥44.20M. The average tenure of the management team and the board of directors is 4.5 years and 4.5 years respectively.

Key information

Zhengqing Liu

Chief executive officer

CN¥1.7m

Total compensation

CEO salary percentage	n/a
CEO tenure	16.8yrs
CEO ownership	1.4%
Management average tenure	4.5yrs
Board average tenure	4.5yrs

Recent management updates

Recent updates

Hunan Hansen Pharmaceutical Co., Ltd.'s (SZSE:002412) Shares Lagging The Market But So Is The Business

Sep 30

CEO

Zhengqing Liu (60 yo)

16.8yrs

Tenure

CN¥1,675,700

Compensation

Mr. Zhengqing Liu has been Chief Executive Officer and Non-Independent Director of Hunan Hansen Pharmaceutical Co., Ltd. since January 20, 2008 and serves as its Chairman since May 25, 2020.

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Zhengqing Liu	Chairman & CEO	16.8yrs	CN¥1.68m	1.42% CN¥ 44.2m
Jianghong Dai	VP, CFO & Board Secretary	4.5yrs	CN¥284.60k	no data
Hua Yang	VP & MD of Hansen Research	3.9yrs	CN¥324.60k	no data
Lingsong Ao	Director & VP	4.4yrs	CN¥888.20k	no data
Jianjun Fu	Director & VP	4.4yrs	CN¥328.20k	no data
Ai Hua Liu	Vice President	13.7yrs	CN¥311.70k	no data

4.5yrs

Average Tenure

53.5yo

Average Age

Experienced Management: 002412's management team is considered experienced (4.5 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Zhengqing Liu	Chairman & CEO	16.8yrs	CN¥1.68m	1.42% CN¥ 44.2m
Lingsong Ao	Director & VP	4.4yrs	CN¥888.20k	no data
Jianjun Fu	Director & VP	4.4yrs	CN¥328.20k	no data
Renhui Fu	Supervisor	13.7yrs	no data	no data
Ping Zhan	Independent Director	4.5yrs	CN¥70.00k	no data
Jinsong Xia	Independent Director	4.5yrs	CN¥70.00k	no data
Gaoyun Hu	Independent Director	4.5yrs	CN¥70.00k	no data
Bingyang Liu	Non-Independent Director	1.5yrs	no data	no data
Chen Chen	Shareholder Supervisor	1.5yrs	no data	no data

4.5yrs

Average Tenure

54yo

Average Age

Experienced Board: 002412's board of directors are considered experienced (4.5 years average tenure).

Hunan Hansen Pharmaceutical Management

Management criteria checks 3/4

Key information

Recent management updates

Hunan Hansen Pharmaceutical Co., Ltd., Annual General Meeting, May 21, 2024

Hunan Hansen Pharmaceutical Co., Ltd., Annual General Meeting, May 21, 2024

Insufficient new directors

Hunan Hansen Pharmaceutical Co., Ltd., Annual General Meeting, May 23, 2023

Recent updates

Third quarter 2024 earnings released: EPS: CN¥0.06 (vs CN¥0.038 in 3Q 2023)

Hunan Hansen Pharmaceutical Co., Ltd. to Report Q3, 2024 Results on Oct 29, 2024

Investor sentiment improves as stock rises 20%

Hunan Hansen Pharmaceutical Co., Ltd.'s (SZSE:002412) Shares Lagging The Market But So Is The Business

Second quarter 2024 earnings released: EPS: CN¥0.084 (vs CN¥0.071 in 2Q 2023)

Hunan Hansen Pharmaceutical Co., Ltd. to Report First Half, 2024 Results on Aug 14, 2024

Hunan Hansen Pharmaceutical Co., Ltd., Annual General Meeting, May 21, 2024

First quarter 2024 earnings released: EPS: CN¥0.12 (vs CN¥0.11 in 1Q 2023)

Hunan Hansen Pharmaceutical Co., Ltd., Annual General Meeting, May 21, 2024

Investor sentiment deteriorates as stock falls 15%

Now 22% undervalued after recent price drop

Hunan Hansen Pharmaceutical Co., Ltd. to Report Q1, 2024 Results on Apr 27, 2024

Now 25% undervalued after recent price drop

Now 27% undervalued after recent price drop

Investor sentiment deteriorates as stock falls 18%

Hunan Hansen Pharmaceutical Co., Ltd. to Report Fiscal Year 2023 Results on Apr 27, 2024

Second quarter 2023 earnings released: EPS: CN¥0.071 (vs CN¥0.054 in 2Q 2022)

Hunan Hansen Pharmaceutical Co., Ltd. Announces Final Cash Dividend on A Shares for the Year 2022, Payable on June 20, 2023

Insufficient new directors

Hunan Hansen Pharmaceutical Co., Ltd., Annual General Meeting, May 23, 2023

Full year 2022 earnings released: EPS: CN¥0.33 (vs CN¥0.27 in FY 2021)

Third quarter 2022 earnings released: EPS: CN¥0.10 (vs CN¥0.085 in 3Q 2021)

Second quarter 2022 earnings released: EPS: CN¥0.054 (vs CN¥0.05 in 2Q 2021)

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Now 22% undervalued after recent price drop

Investor sentiment improved over the past week

Now 24% undervalued

Now 21% undervalued

Now 23% undervalued

Investor sentiment improved over the past week

Third quarter 2021 earnings released: EPS CN¥0.085 (vs CN¥0.063 in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.05 (vs CN¥0.032 in 2Q 2020)

First quarter 2021 earnings released: EPS CN¥0.091 (vs CN¥0.073 in 1Q 2020)

New 90-day low: CN¥5.78

New 90-day low: CN¥6.17

New 90-day high: CN¥7.46

New 90-day low: CN¥6.66

Third quarter earnings released

Hunan Hansen Pharmaceutical Co., Ltd. to Report Q3, 2020 Results on Oct 27, 2020

New 90-day low: CN¥6.77

First half earnings released

New 90-day high - CN¥8.17

Hunan Hansen Pharmaceutical Co., Ltd. to Report First Half, 2020 Results on Aug 21, 2020

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age